Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Estos medicamentos se administran principalmente mediante inyeccin subcutnea con frecuencias que varan desde diaria hasta semanal, dependiendo de la formulacin especfica
Wegovy is approved for chronic weight management in obesity or overweight with comorbidities, and as of March 2024, for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight
If you miss 2 or more consecutive doses, contact your healthcare provider (you may need to re-titrate)
Based on Phase 3 trial data, Retatrutide appears to produce greater average weight loss than semaglutide (the active ingredient in Wegovy and Ozempic)
US$ 29.66
US$ 22.03
US$ 21.62
US$ 28.07
